References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailReturn-To-Play criteria after hamstring injury: actual medicine practice in professional soccer
Delvaux, François ULg; Rochcongar, Pierre; Bruyère, Olivier ULg et al

Poster (2013, April 25)

Detailed reference viewed: 150 (12 ULg)
Full Text
Peer Reviewed
See detailRole of nutraceuticals in the symptomatic and structural management of osteoarthritis
Bruyère, Olivier ULg

in Osteoporosis International (2013, April), 24(Suppl.1), 82-83

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailNonpharmacological management
Bruyère, Olivier ULg

in Osteoporosis International (2013, April), 24(Suppl.1), 76

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailReproducibility of joint space width assessment when external calibration on the radiograph is missing
DEROISY, Rita ULg; Reginster, Jean-Yves ULg; Bruyère, Olivier ULg

in Osteoporosis International (2013, April), 24(Suppl.1), 379

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailValidity of the French hip and knee replacement expectations surveys
NEUPREZ, Audrey ULg; François, Garance ULg; Delcour, JP et al

in Osteoporosis International (2013, April), 24(Suppl.1), 374

Detailed reference viewed: 36 (19 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the impact of a 6-month training by whole body vibration on the risk of falls among nursing home residents
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Demonceau, Marie ULg et al

in Osteoporosis International (2013, April), 24(Suppl.1), 246-247

Detailed reference viewed: 30 (12 ULg)
Full Text
Peer Reviewed
See detailClinical characteristics of patients responsive to whole body vibration
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Maquet, Didier ULg et al

in Osteoporosis International (2013, April), 24(Suppl.1), 243

Detailed reference viewed: 37 (10 ULg)
Full Text
Peer Reviewed
See detailQuantitative gait assessment using an accelerometer technology as a predictive tool of falls among nursing home residents: a 6-month prospective study
Bruyère, Olivier ULg; Detalle, Anne-Sophie; Demonceau, Marie ULg et al

in Osteoporosis International (2013, April), 24(Suppl.1), 210

Detailed reference viewed: 12 (4 ULg)
Full Text
Peer Reviewed
See detailChanges in the structure and the symptoms of the osteoarthritis knee and prediction of future knee replacement over an 8-year follow-up period
Bruyère, Olivier ULg; Cooper, Cyrus; Pavelka, Karel et al

in Osteoporosis International (2013, April), 24(Suppl.1), 209

Detailed reference viewed: 29 (16 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of vitamin D and calcium supplementation in the treatment of postmenopausal women
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Rabenda, Véronique ULg et al

in Osteoporosis International (2013, April), 24(Suppl.1), 198

Detailed reference viewed: 26 (4 ULg)
Full Text
Peer Reviewed
See detailWhat is the predictive value of MRI for the occurrence of hard clinical endpoints in knee osteoarthritis?
Pelletier, Jean-Pierre; Peterfy, Charles; Brandi, Maria Luisa et al

in Osteoporosis International (2013, April), 24(Suppl.1), 84-85

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailHealth economics in osteoarthritis
Hiligsmann, Mickaël ULg; Cooper, Cyrus; Arden, Nigel et al

in Osteoporosis International (2013, April), 24(Suppl.1), 79-80

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailWhat is the value of biomarkers for drug development in osteoarthritis?
Lotz, Martin; Martel-Pelletier, Johanne; Christiansen, Claus et al

in Osteoporosis International (2013, April), 24(Suppl.1), 77-78

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailQuality of life in sarcopenia and frailty
Rizzoli, René; Reginster, Jean-Yves ULg; Arnal, Jean-François et al

in Osteoporosis International (2013, April), 24(Suppl.1), 76-77

Detailed reference viewed: 38 (13 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate improves osteoarthritis symptoms compared to placebo in patients with knee OA: The SEKOIA study
Bruyère, Olivier ULg; Richette, P; Bellamy, N et al

in Osteoporosis International (2013, April), 24(Suppl.1), 49-51

Detailed reference viewed: 31 (4 ULg)
Full Text
Peer Reviewed
See detailSafety concerns with the long-term management of osteoporosis
Reginster, Jean-Yves ULg; Pelousse, Franz; Bruyère, Olivier ULg

in Expert Opinion on Drug Safety (2013)

Introduction: Postmenopausal osteoporosis is a chronic disease that exerts a significant burden on both individuals and the community. Hence, there is a requirement for long-term treatment to be ... [more ▼]

Introduction: Postmenopausal osteoporosis is a chronic disease that exerts a significant burden on both individuals and the community. Hence, there is a requirement for long-term treatment to be associated with a positive benefit-risk balance. Areas covered: In this descriptive review, the long-term safety of calcitonin, selective estrogen receptor modulators (SERMs), bisphosphonates, denosumab and strontium ranelate was reviewed based on randomized controlled trials of 3 years or longer supplemented by extension study data and data from large, observational studies. Expert opinion: Rare adverse events become apparent with all currently available treatments for osteoporosis with long-term therapy. Due to the rarity of these adverse events and to the worldwide burden of osteoporosis, the benefit- risk balance remains in favor of the beneficial effects of treatment on an outcome rather than the probability of an adverse effect. No single antiosteoporosis agent is appropriate for all patients. Treatment decisions should be made on an individual basis, taking into account the relative benefits and risks in different patient populations. [less ▲]

Detailed reference viewed: 16 (6 ULg)
Full Text
Peer Reviewed
See detailCreatinine - or cystatin C - based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease
DELANAYE, Pierre ULg; CAVALIER, Etienne ULg; Moranne, Olivier et al

in BMC Nephrology (2013), 14

Chronic kidney disease (CKD) is a major issue in public health. Its prevalence has been calculated using estimation of glomerular filtration rate (GFR) by the creatinine-based equations developed in the ... [more ▼]

Chronic kidney disease (CKD) is a major issue in public health. Its prevalence has been calculated using estimation of glomerular filtration rate (GFR) by the creatinine-based equations developed in the Modified Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) study. Recently, new equations based either on cystatin C (CKD-EPI Cys) or both cystatin and creatinine (CKD-EPI mix) have been proposed by the CKD-EPI consortium. The aim of this study was to measure the difference in the prevalence of stage 3 CKD, defined as an estimated GFR less than 60 mL/min/1.73 m2, in a population using these four equations. METHODS: CKD screening was performed in the Province of Liege, Belgium. On a voluntary basis, people aged over 50 years have been screened. GFR was estimated by the four equations. Stage 3 CKD was defined as a GFR less than 60 mL/min/1.73 m2. RESULTS: The population screened consisted of 4189 people (47% were men, mean age 63 +/- 7y). Their mean serum creatinine and plasma cystatin C levels were 0.88 +/- 0.21 mg/dL and 0.85 +/- 0.17 mg/L, respectively. The prevalence of CKD in this population using the MDRD, the CKD-EPI, the CKD-EPI Cys and the CKD-EPI mix equations was 13%, 9.8%, 4.7% and 5%, respectively. The prevalence of CKD was significantly higher with the creatinine-based (MDRD and the CKD-EPI) equations compared to the new cystatin C-based equations. CONCLUSIONS: Prevalence of CKD varies strongly depending on the method used to estimate GFR. Such discrepancies are of importance and must be confirmed and explained by additional studies, notably by studies using GFR measured with a reference method [less ▲]

Detailed reference viewed: 48 (19 ULg)
Full Text
Peer Reviewed
See detailHealth Technology Assessment in Osteoporosis.
Hiligsmann, Mickaël ULg; Kanis, John A.; Compston, Juliet et al

in Calcified Tissue International (2013)

We review the various aspects of health technology assessment in osteoporosis, including epidemiology and burden of disease, and assessment of the cost-effectiveness of recent advances in the treatment of ... [more ▼]

We review the various aspects of health technology assessment in osteoporosis, including epidemiology and burden of disease, and assessment of the cost-effectiveness of recent advances in the treatment of osteoporosis and the prevention of fracture, in the context of the allocation of health-care resources by decision makers in osteoporosis. This article was prepared on the basis of a symposium held by the Belgian Bone Club and the discussions surrounding that meeting and is based on a review and critical appraisal of the literature. Epidemiological studies confirm the immense burden of osteoporotic fractures for patients and society, with lifetime risks of any fracture of the hip, spine, and forearm of around 40 % for women and 13 % for men. The economic impact is also large; for example, Europe's six largest countries spent <euro>31 billion on osteoporotic fractures in 2010. Moreover, the burden is expected to increase in the future with demographic changes and increasing life expectancy. Recent advances in the management of osteoporosis include novel treatments, better fracture-risk assessment notably via fracture risk algorithms, and improved adherence to medication. Economic evaluation can inform decision makers in health care on the cost-effectiveness of the various interventions. Cost-effectiveness analyses suggest that the recent advances in the prevention and treatment of osteoporosis may constitute an efficient basis for the allocation of scarce health-care resources. In summary, health technology assessment is increasingly used in the field of osteoporosis and could be very useful to help decision makers efficiently allocate health-care resources. [less ▲]

Detailed reference viewed: 21 (10 ULg)